CLEAR Outcomes Company Update Call: Detailed Results Discussion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Esperion Therapeutics (ESPR) to Buy at Jefferies ahead of ACC
February 24, 2023 11:34 AM ESTJefferies upgraded Esperion Therapeutics (NASDAQ: ESPR) to a Buy rating (From Hold) and doubled the price target on the stock to $6.00 (From $12.00) following incrementally positive management comments heading into the CLEAR CV outcomes data at ACC on March 4th.
Jefferies analysts are confident ESPR should meet or beat the Street's 15% cardiovascular benefit "bar," but even... More
